GlassScriptPhysician profile
Natalie Bateson
NPI 1033589023
$3,956.20
in general payments reported to CMS, 2019-2025
28 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.15 · 2022: $458 · 2023: $431 · 2024: $812 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393 · Education: $44.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.60 |
| Education | $44.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $902.81 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $542.04 | 2022-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $335.07 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $310.06 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $304.17 | 2022-2025 | Prolastin-C Liquid |
| Insmed, INC. | $251.86 | 2024-2025 | Arikayce, Brinsupri |
| Amgen INC. | $213.30 | 2024-2025 | Tezspire, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $193.96 | 2022-2025 | Glassia |
| Viatris Specialty LLC | $110.85 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.05 | 2025 | Jascayd, Ofev |
| Baxter Healthcare | $86.01 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $77.38 | 2023-2025 | Acthar |
| Verona Pharma, INC. | $70.07 | 2025 | Ohtuvayre |
| Electromed, INC. | $62.82 | 2024-2025 | Smartvest |
| Genentech USA, INC. | $61.15 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $51.01 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $35.33 | 2025 | Opsumit, Opsynvi, Uptravi |
| Philips North America LLC | $34.99 | 2025 | Vest Therapy Und |
| Inogen, INC. | $34.01 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $32.53 | 2025 | Zerbaxa |
| Mylan Specialty L.P. | $31.42 | 2022-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $25.12 | 2024 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $18.25 | 2024 | Veklury |
| Lilly USA, LLC | $17.50 | 2025 | Zepbound |
| Pulmonx Corporation | $17.14 | 2022 | |
| Nabriva Therapeutics, Plc | $16.93 | 2022 | |
| Caris Mpi, INC. | $14.24 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Bateson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.